Stockscreener 앱 받기
266.11
0.61%
1.61
Alnylam Pharmaceuticals Inc 주식(ALNY)의 최신 뉴스
Alnylam Pharmaceuticals (ALNY) Could Be 39% Undervalued On Fresh ESC 2026 Data - simplywall.st
Alnylam Pharmaceuticals (NASDAQ:ALNY): Affordable Growth in Biotech - ChartMill
ALNY Stock Climbs As Analysts Turn Bullish After ESC Data - StocksToTrade
ALNY Stock Rebounds As Analysts Back RNAi Momentum - timothysykes.com
ALNY Stock Rebounds As Analysts Back RNAi Growth Story - timothysykes.com
Alnylam Pharmaceuticals Inc Stock (ALNY) Moved Up by 7.90% on Sep 2: Facts Behind the Movement - TradingKey
Alnylam Pharmaceuticals gains as investors digest fresh ESC data and upcoming conference appearances - Quiver Quantitative
Alnylam to Webcast Presentations at Upcoming September Investor Conferences - Business Wire
ALNY Reiterated by HC Wainwright & Co. -- Price Target Maintained at $455 - GuruFocus
Analysts Are Bullish on These Healthcare Stocks: Boston Scientific (BSX), Alnylam Pharma (ALNY) - The Globe and Mail
Expanded RNAi Cardio Data Might Change The Case For Investing In Alnylam Pharmaceuticals (ALNY) - simplywall.st
Alnylam Pharmaceuticals (ALNY) Investor Outlook: Exploring a 56% Potential Upside in Biotech Innovation - DirectorsTalk Interviews
Alnylam data support Amvuttra across ATTR patient groups, advance hypertension drug case (ALNY:NASDAQ) - Seeking Alpha
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings - finance.yahoo.com
If You Invested $100 In Alnylam Pharmaceuticals Stock 20 Years Ago, You Would Have This Much Today - Benzinga
Alnylam drops as AstraZeneca posts full trial results for failed heart drug - Seeking Alpha
Why Everyone Is Watching Alnylam Pharmaceuticals (ALNY) Today - simplywall.st
ALNY INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Alnylam Pharmaceuticals, Inc. - GlobeNewswire
Alnylam to Present New Data Reinforcing Strength in RNAi-Powered TTR Silencing and Continued Progress in Hypertension at ESC Congress 2026 - Business Wire
Alnylam Pharmaceuticals, Inc. (ALNY) Stock Analysis: A Biotech Leader with 56.72% Potential Upside - DirectorsTalk Interviews
Why Amylyx Pharmaceuticals Blasted Nearly 79% Higher This Week - AOL.com
Silvant Capital Management LLC Takes $5.46 Million Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Wealthfront Advisers LLC Makes New Investment in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
NewEdge Wealth LLC Takes Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Biotech Is Booming, But These 2 Stocks Missed the Memo - Sahm
Danske Bank A S Takes $19.43 Million Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Lowered TTR Sales Outlook And Legal Probe Might Change The Case For Investing In Alnylam (ALNY) - simplywall.st
Bragar Eagel & Squire, P.C. is Investigating Alnylam - GlobeNewswire
Securities Fraud Investigation Into Alnylam - GlobeNewswire
Alnylam Pharmaceuticals (NASDAQ:ALNY) Upgraded to "Strong-Buy" at BMO Capital Markets - MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY): A Value Stock Worthy of Investor Attention - ChartMill
Mitsubishi UFJ Asset Management Co. Ltd. Makes New Investment in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
NewEdge Advisors LLC Trims Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
E Fund Management Co. Ltd. Acquires New Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
(NASDAQ: ALNY): Investigation Launched Into Alnylam Pharmaceuticals, Inc. by Kessler Topaz Meltzer & Check, LLP - Barchart.com
ALNY SHAREHOLDER ALERT: Alnylam Pharmaceuticals, Inc. Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations - Business Wire
Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz - WBOC TV
NASDAQ: ALNY: Kessler Topaz Meltzer & Check, LLP Launches Investigation Into Alnylam Pharmaceuticals, Inc. - NewMediaWire
Why Alnylam Pharmaceuticals (ALNY) Stock Is Up Today - Quiver Quantitative
Alnylam initiated an outperform at BMO on RNAi pipeline - Seeking Alpha
BMO Capital Markets Initiates Coverage on Alnylam Pharmaceuticals (NASDAQ:ALNY) - MarketBeat
This Alnylam Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For We - Benzinga
BMO initiates Alnylam stock with outperform on ATTR franchise growth By Investing.com - Investing.com Canada
ALNY Initiated Coverage by BMO Capital -- Rating Set to Outperfo - GuruFocus
Why the Alnylam Sell-Off Looks Overdone -- and What Investors Are Missing - AOL.com
ALNY ALERT: Investigation Launched Into Alnylam Pharmaceuticals, Inc., Investors Are Encouraged to Contact KTMC Law Firm - NewMediaWire
ALNY Looks 56.8% Undervalued on GF Value™ - GuruFocus
Familial Amyloid Polyneuropathy Market - Future Market Insights
ALNY Looks 56.7% Undervalued on GF Value™ - GuruFocus
Alnylam Pharmaceuticals (ALNY): Investor Outlook With A 62.82% Potential Upside - DirectorsTalk Interviews
ALNY Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) Investors to Contact the Firm - The Globe and Mail
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Alnylam Pharmaceuticals, Inc. (ALNY) And Encourages Shareholders to Reach Out - ACCESS Newswire
Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) Investors to Contact the Firm - PR Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
S&CO Inc. Acquires New Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
SCS Capital Management LLC Invests $34.78 Million in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals Is Maintained at Equal-Weight by Wells Fargo - Moomoo
Kessler Topaz Meltzer & Check, LLP Encourages Alnylam - GlobeNewswire
Alnylam Pharma (ALNY) Gets a Hold from Wells Fargo - The Globe and Mail
NASDAQ: ALNY Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) Investors to Contact the Firm - The AI Journal
ALNY Maintains Equal-Weight by Wells Fargo -- Price Target Lowered to $256 - GuruFocus
Alnylam Pharmaceuticals (NASDAQ:ALNY) Given New $256.00 Price Target at Wells Fargo & Company - MarketBeat
Alnylam Pharmaceuticals (ALNY) Cuts Guidance As Undervalued Narrative Faces A Tougher Test - simplywall.st
Stifel Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $318 - Moomoo
1.22%
0.13%
자본화:
|
볼륨(24시간):